SHR1459 in Combination With YY-20394 in Recurrent and Refractory B-cell Non-Hodgkin's Lymphoma
Status:
Recruiting
Trial end date:
2023-10-01
Target enrollment:
Participant gender:
Summary
The study is evaluating the efficacy, and safety of SHR1459 combined with YY-20394 for
Recurrent and refractory B-cell non-Hodgkin's lymphoma in adults.